8-K: Prelude Therapeutics Reports Positive Clinical Data and Financial Update for Q3 2024

Prelude Therapeutics announced encouraging clinical data for its SMARCA2 degrader programs and a solid cash position extending into 2026.

Summary

• Prelude Therapeutics reported its third quarter 2024 financial results and provided a corporate update.
• The company presented interim data from the Phase 1 study of PRT3789, an intravenous SMARCA2 degrader, showing clinical proof of concept in SMARCA4-mutated cancers.
• A Phase 1 trial was initiated for PRT7732, an oral SMARCA2 degrader, also targeting SMARCA4-mutated cancers.
• Preclinical data from the Precision ADC platform, using SMARCA2/4 degrader payloads, was presented.
• Interim data for the CDK9 inhibitor, PRT2527, in hematological malignancies will be presented at the American Society of Hematology Annual Meeting in December 2024.
• The company's cash runway extends into 2026, with $153.6 million in cash, cash equivalents, and marketable securities as of September 30, 2024.
• Research and development expenses for the third quarter of 2024 were $29.5 million, up from $26.3 million in the prior year period.
• General and administrative expenses for the third quarter of 2024 were $7.9 million, up from $7.1 million in the prior year period.
• The net loss for the third quarter of 2024 was $32.3 million, or $0.43 per share, compared to $30.6 million, or $0.45 per share, for the same period in 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong clinical data, a solid cash runway, and strategic collaborations. The company is making significant progress in its clinical programs, and the management commentary is optimistic. While there are risks associated with drug development, the overall tone is very positive.

Positives

• The company has demonstrated clinical proof of concept for its lead SMARCA2 degrader, PRT3789.
• The initiation of a Phase 1 trial for the oral SMARCA2 degrader, PRT7732, expands the company's pipeline.
• The presentation of preclinical data for the Precision ADC platform highlights the potential of SMARCA2/4 degrader payloads.
• The company's strong cash position provides a runway into 2026.
• The collaboration with Pfizer Ignite provides access to valuable resources and expertise.
• PRT3789 has shown an acceptable safety profile in combination with docetaxel.
• The company is advancing multiple clinical programs, including PRT3789, PRT7732, and PRT2527.
• The company is exploring combinations of PRT3789 with other therapies, such as docetaxel and pembrolizumab.
• The company is developing a portfolio of SMARCA-targeted precision medicines.

Negatives

• The company reported a net loss of $32.3 million for the third quarter of 2024.
• Research and development expenses increased to $29.5 million for the third quarter of 2024.
• General and administrative expenses increased to $7.9 million for the third quarter of 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including the ability to advance product candidates and obtain regulatory approvals.
• Clinical trial results are inherently uncertain, and there is no guarantee of success.
• The company's ability to fund development activities and achieve development goals is subject to risks.
• The company faces risks related to supply chain and manufacturing facilities.
• The company's ability to protect intellectual property is subject to risks.

Future Outlook

The company anticipates that its existing cash, cash equivalents, and marketable securities will fund operations into 2026. They also expect to report progress on their SMARCA2 degrader programs beginning early 2025 and continue to advance their clinical programs.

Management Comments

• Kris Vaddi, Ph.D., Chief Executive Officer of Prelude, stated that the third quarter was marked by dedicated execution and the achievement of essential milestones for their lead clinical programs targeting SMARCA2.
• Dr. Vaddi noted the demonstration of the first-ever clinical proof of concept with PRT3789 in patients with aggressive SMARCA4 mutated cancers.
• Dr. Vaddi also highlighted the commencement of patient enrollment for PRT7732, the oral SMARCA2 degrader.

Industry Context

This announcement is significant in the context of precision oncology, as Prelude is developing novel therapies targeting SMARCA2, a key protein in cancer development. The company's focus on targeted protein degradation and the development of both intravenous and oral SMARCA2 degraders, as well as Precision ADCs, positions them as a leader in this emerging field. The collaboration with Pfizer Ignite also highlights the growing interest in this area.

Comparison to Industry Standards

• The reported objective response rate (ORR) of 22.2% in NSCLC patients with Class I SMARCA4 mutations treated with PRT3789 at doses of 283 mg or higher compares favorably to the 21.9% ORR reported for first-line SMARCA4-mutated NSCLC treated with chemoimmunotherapy in a study by Alessi et al.
• The median progression-free survival (PFS) of 2.7 months for first-line SMARCA4-mutated NSCLC treated with chemoimmunotherapy, as reported by Alessi et al., highlights the unmet need that Prelude's therapies are aiming to address.
• The development of SMARCA2 degraders is a novel approach, as traditional inhibitors have faced challenges in achieving both potency and selectivity. Companies like Foghorn/Lilly and Novartis have previously explored SMARCA2 inhibition with less success.
• The use of a SMARCA2/4 dual degrader payload in Precision ADCs is a unique approach, as most approved ADCs use cytotoxic payloads. This strategy could potentially expand the reach of ADCs to cancers that do not currently benefit from targeted therapies.
• The company's focus on both intravenous and oral SMARCA2 degraders provides optionality for patients and differentiates them from companies focusing on a single modality.

Stakeholder Impact

• Shareholders will likely view the positive clinical data and strong cash position favorably.
• Employees may be encouraged by the company's progress and future prospects.
• Patients with SMARCA4-mutated cancers may benefit from the development of new treatment options.
• The collaboration with Pfizer Ignite may provide access to valuable resources and expertise for the company.

Next Steps

• The company expects to conclude monotherapy dose escalation for PRT3789 by year-end 2024 and identify a dose for advancement to registrational trials.
• The company will continue to enroll patients in back-fill cohorts enriched for NSCLC and SMARCA4 loss-of-function mutations.
• The company will continue to enroll patients in the combination with docetaxel cohort.
• The company will continue to enroll patients in the Phase 2 clinical trial evaluating PRT3789 in combination with KEYTRUDA (pembrolizumab).
• The company will present interim Phase 1 data for PRT2527 at the American Society of Hematology Annual Meeting in December 2024.
• The company will report progress on both the PRT3789 and PRT7732 programs beginning early 2025.

Key Dates

Keywords

SMARCA2 degrader, PRT3789, PRT7732, Precision ADC, CDK9 inhibitor, PRT2527, oncology, cancer, clinical trial, targeted therapy, protein degradation, hematological malignancies, SMARCA4 mutation